期刊文献+

培美曲塞/吉西他滨分别联合顺铂对肺腺癌术后化疗的临床疗效观察 被引量:8

Clinical effect of pemetrexed gemcitabine respectively with cisplatin treatment of postoperative patients with lung adenocarcinoma
下载PDF
导出
摘要 目的:观察培美曲塞(PMD)与吉西他滨(GEM)分别联合顺铂辅助治疗肺腺癌术后的疗效及毒副反应。方法:回顾性分析符合条件的115例肺腺癌术后患者,其中PP(PMD联合顺铂)组56例和GP(GEM联合顺铂)组59例,每例均完成4个周期辅助化疗,观察术后复发率及化疗毒副反应。结果:PP组疾病控制率94.6%,GP组疾病控制率91.5%,两组相比较术后复发率无统计学意义(P>0.05)。化疗毒副反应主要是骨髓抑制、胃肠反应、脱发、皮肤瘙痒等。PP组化疗毒副反应显著低于GP组,有统计学意义(P<0.05)。结论:PMD联合顺铂与GEM联合顺铂辅助治疗肺腺癌术后,两者治疗效果无明显差异,但PMD联合顺铂化疗毒副反应明显较轻,可作为肺腺癌术后辅助化疗的优先推荐用药。 Objective :To observe the curative effects and sid- effects of the adjuvant treatment to postoperative patients with lung adenocarcinoma after given pemetrexed(PMD) and gemcitabine (GEM) respectively with cisplatin. Methods:Retrospectively analyze 115 eligible postoperative patients with lung adenocarcinoma ,56 of PP group and 59 of GP group, accomplished 4 -periodic adjuvant chemotherapy and observe their recurrence rate and side - effects. Results: There was no statistical significance ( P 〉 0.05 ) of the recurrence rate between PP group with the disease control rate of 94.6% and GP group 91.5%. The main side - effects of chemotherapy were myelosuppression,gastro- intestinal reaction, aopecia, cutaneous pruritus. The side - effects of PP group were dramaticlly fewer than those of GP group(P 〈 0.05). Conclusion: There was no obvious difference of cure postoperative patients with either PEM with cisplatin or GEM with cisplatin, however, GEM with cisplatinhas has fewer side - effects significantly. PEM can be preferentially recommended as an adjuvant chemotherapy of postoperative patients with lung adenocarcinoma.
出处 《现代肿瘤医学》 CAS 2014年第4期837-839,共3页 Journal of Modern Oncology
关键词 培美曲塞 吉西他滨 肺腺癌术后 化疗 pemetrexed gemcitabine lung adenocarcinoma chemotherapy
  • 相关文献

参考文献15

  • 1哈楠,计凤妹.2002~2007年上海市松江区肺癌发病情况分析[J].中国肿瘤,2011,20(12):889-892. 被引量:9
  • 2栾丽伟,赵智辅,金鑫,张杰.顺铂分别联合培美曲塞和多西他赛治疗晚期肺腺癌的临床观察与分析[J].中国医药指南,2012,10(5):188-189. 被引量:3
  • 3Arriagada R,Bergman B,Dunant A,et al.Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer[J].N Engl J Med,2004,350:351-360.
  • 4Scagliotti GV,Parikh P,Von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus PMD etrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
  • 5Manegold C,Schmid-Bindert G,Pilz LR.Pemetrexed for the treatment of non-small-cell lung cancer[J].Drug Profile,2009,9(9):1195-1209.
  • 6张咏梅,霍伟,曲范杰.培美曲塞一线治疗老年晚期肺腺癌临床观察[J].当代医学,2012,18(4):59-60. 被引量:2
  • 7Laskin JJ,Nicholas G,Lee C,et al.Phase Ⅰ/Ⅱ trial of custirsen (OGX-011),an inhibitor of clusterin,in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non small cell lung cancer[J].J Thorac Oncol,2012,7(3):579-586.
  • 8Li L,Schaid DJ,Fridley BL,et al.Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer[J].Pharmacogenet Genomics,2012,22 (2):105-116.
  • 9任必勇,张军,刘学芬.泽菲应用于肿瘤治疗的最新进展[J].重庆医学,2010,39(14):1917-1920. 被引量:6
  • 10Scagliotti G,Hanna N,Fossella F,et al.The differential efficacy of Pemetrexed according to NSCLC histology:a review of two phase Ⅲ studies[J].Oncologist,2009,14(3):253-263.

二级参考文献41

共引文献30

同被引文献63

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部